Ovarian Reserve Markers in Girls with Sickle Cell Disease
Compares AMH hormone levels in girls with sickle cell disease with healthy girls during puberty.
Key facts
- Who runs it
- St. Jude Children's Research Hospital
- Where
- Memphis, United StatesSee the site
- Trial code
- Registry title
- Functional Ovarian Reserve in Sickle Cell Disease
- Status
- Recruiting
- People taking part
- 440 people, planned
- Started
- 2 Jun 2026
- Expected to end
- Feb 2034
- Type of study
- Observational, 2 groups
- Record updated
- 4 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for girls and young women aged 10 to 18 with sickle cell disease, and healthy female controls of similar race or ethnicity. It studies ovarian reserve (AMH level) during puberty.
- Age
- 10 years to under 19 years (the record lists 10 to 18 years).
- Sex
- Females only.
- Disease stage
- Sickle cell disease of any genotype. Healthy controls (a sibling, relative, household member, or other female of similar race/ethnicity) can also join.
- Earlier treatment
- People who had a stem cell transplant or gene therapy cannot join.
Main reasons for not taking part
- Had a hematopoietic stem cell transplant or gene therapy before joining
- Preparing for a stem cell transplant or gene therapy
- Cannot or will not give written informed consent (self or legal guardian)
- Pregnancy
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Sickle cell disease of any genotype or a healthy sibling, relative, household member, or other females of similar race/ethnicity of a patient with sickle cell disease
- Age at enrollment ≥ 10 years and < 19 years
- Females
Who cannot take part
- History of hematopoietic stem cell transplantation or gene therapy prior to enrollment or preparing for hematopoietic stem cell transplantation or gene therapy prior to enrollment
- Inability or unwillingness of research participant or legal guardian/representative to give written informed consent
- Pregnancy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 10 and 18 years old?
Where in United States
- St. Jude Children's Research HospitalMemphis, United StatesContact: Christine Yu, MDTaking people
About the trial
What the trial wants to find out
This study aims to look at AMH levels in female children with SCD as they go through puberty to see if they are at the same level as other children without SCD at the same age and/or pubertal stage and will also look at how treatment exposures and pain crises affect the AMH levels in children with SCD.
Read full original descriptionShow less
Primary Objective:
* To evaluate whether AMH levels are lower in pre-teens and adolescent females with SCD when compared with healthy female controls (siblings, relatives, non-relatives of similar race/ethnicity) at the same age and pubertal stage.
Secondary Objectives:
* To evaluate whether AMH has a similar trajectory in female pre-teens and adolescents with SCD when compared with the general population and controls. * To describe pubertal timing, menstrual history, and markers of functional ovarian reserve (FOR), as well as prevalence of premature ovarian insufficiency (POI) as determined by medical history and laboratory markers in pre-teens and adolescents with SCD in comparison with their female controls. * To correlate AMH levels with FSH and estradiol levels, normal pubertal timing, and menstrual history in children and adolescents with SCD. * To correlate the severity of SCD (number of vaso-occlusive events) with pubertal timing, presence of normal vs abnormal menstruation, and laboratory markers of FOR, in pre-teens and adolescents with SCD. * To correlate the use of SCD modifying treatment modalities with pubertal timing, menstrual pattern, and laboratory markers of FOR in pre-teens and adolescents with SCD.
The 2 groups in the trial
- Participants with Sickle Cell Disease
Females with sickle cell disease, all genotypes (age at enrollment ≥ 10 years and \< 19 years)
- Healthy Controls
Healthy female siblings/relatives of patients with SCD (including those with sickle cell trait), and other females of similar race/ethnicity (age at enrollment ≥ 10 years and \< 19 years)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Functional Ovarian Reserve in Sickle Cell Disease
- Plain-language title
- Ovarian Reserve Markers in Girls with Sickle Cell DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07392216, who can take part
- Record updated
- 4 June 2026